Drugs / TAS-205
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02752048 | May 2016 → May 2017 | Duchenne muscular dystrophy | Taiho Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04587908 | Nov 2020 → May 2027 expected | Duchenne muscular dystrophy | Taiho Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02246478 Comparator | Sep 2014 → Jun 2015 | Duchenne muscular dystrophy | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS-205 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04587908 ↗ |
| Action | Inhibit | “novel selective HPGDS inhibitor” PMID 31957953 ↗ Jan 2020 |
| Route | Oral | “single oral administration after meals” NCT02246478 ↗ |
| Target | HPGDS | “novel selective HPGDS inhibitor” PMID 31957953 ↗ Jan 2020 |